Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
This occurred despite similar weight loss between groups
Week 58:Hyperpigmentation reduced
Mochi Health has also offered compounded semaglutide during periods of FDA-declared shortage, a practice the FDA has warned consumers about given quality-control risks at some 503A compounding pharmacies [1]
(Bron: Diabetes Fonds, EenVandaag, Science, Thuisarts.nl, Apotheek.nl, De Tafel van Gert, 24Pharma.nl, Instituut Verantwoord Medicijngebruik, RTL Nieuws, De Volkskrant, NRC, Nederlandslank.nl
Curious if weight loss medication could be part of your sleep apnea journey
